Immunomedics, Inc. (IMMU) Release: 90Y-Epratuzumab Study Shows Improvement of Therapy Results Following R-CHOP
6/11/2013 9:26:08 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, June 10, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that adding two doses of epratuzumab labeled with the radioisotope, yttrium-90 (90Y), to a combination of rituximab and CHOP chemotherapy (R-CHOP), the standard of care for patients with diffuse large B-cell lymphoma (DLBCL), appeared to improve elderly patients' responses to treatment.
Help employers find you! Check out all the jobs and post your resume.
comments powered by